Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 

2025 American Society of Clinical Oncology (ASCO) Annual Meeting

 featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.

Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University Health Stephenson Cancer Center and serves as an ambassador for ASCO.

The group highlighted several late-breaking abstracts, plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:

Phase 1b/2 CARTITUDE-1 trial (NCT03548207, NCT05201781)

Long-term follow-up showed that approximately one-third (33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti).

An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.

With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-not evaluable [NE]).

Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use

Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.

Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.

Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.

Phase 1b/2 NEXICART-2 trial (NCT06097832)

Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.

Among 12 patients who received the agent at 450 x 10

 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively.

With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.

Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). 

2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.7507

Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). 

2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.7023

Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. 

2025;43(suppl 16):7508. doi:10.1200/JCO.2025.43.16_suppl.7508

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Biochemical recurrence can be a clinical tightrope walk. The latest Oncology Decoded episode highlights prostate-specific membrane antigen (PSMA) PET imaging, offering a practical, expert-led exploration of how this advanced modality is moving beyond theoretical benefits to become a cornerstone in the management of advanced prostate cancer.

Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers;

Benjamin Garmezy, MD, associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at SCRI and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, underscored the curative potential of adjuvant therapy in kidney cancer; 

Mike Lattanzi, MD, a genitourinary medical oncologist from Texas Oncology; 

Damian N. Sorce, MD, a urologist from Colorado Urology.

A key theme throughout the episode was the practical application of PSMA PET scans. The panelists share their experiences and insights on how PSMA imaging is impacting risk stratification in patients with prostate cancer. They discuss its role in identifying early metastatic disease, particularly in the context of biochemical recurrence after primary treatment. The ability of PSMA PET to detect bone lesions and lymph node involvement with greater sensitivity and specificity compared with conventional imaging is highlighted as a significant advantage in guiding treatment decisions.

The conversation touches upon the integration of PSMA imaging with established treatment modalities, such as androgen deprivation therapy (ADT) and radiation therapy. The experts discuss how PSMA findings can influence the timing and extent of these treatments, potentially leading to more personalized and effective approaches. For instance, the identification of oligometastatic disease through PSMA PET may guide the use of targeted therapies like stereotactic body radiation therapy (SBRT) in conjunction with systemic therapies.

Risk stratification emerges as a crucial aspect of utilizing PSMA imaging effectively. The panelists discuss how PSMA results can help differentiate between patients with localized recurrence amenable to salvage therapy and those with more widespread disease requiring systemic intervention. This improved risk assessment allows clinicians to tailor treatment strategies, potentially avoiding overtreatment in some cases and ensuring timely and aggressive therapy in others.

The importance of a multidisciplinary care team is implicitly underscored throughout the discussion. The interaction between urologists and oncologists, as represented by the panelists, highlights the need for seamless collaboration in interpreting PSMA imaging results and formulating comprehensive treatment plans for patients with advanced prostate cancer.

Experts weigh in on the practical applications of PSMA PET imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging  

In this episode, CancerNetwork® spoke with Eric Winer, MD, director of the Yale Cancer Center; president and physician-in-chief at Smilow Cancer Hospital; deputy dean for cancer research, Alfred Gilman Professor of Pharmacology, and Professor of Medicine at Yale School of Medicine; and chair of the association board for the American Society of Clinical Oncology (ASCO), about the current state of oncologist burnout, steps that can be taken to ameliorate it, and how it currently impacts professionals in the field.

Causes of workplace burnout that authors identified in a paper published in the 

 in January 2025 included the use of electronic health records, staffing levels, payer authorizations, hours worked, and age. Additionally, published results from the survey revealed a 14% increase in the rate of oncologists who experienced workplace burnout from 2013 to 2023 (

<.01). Moreover, a significant correlation between being a caregiver for someone at home and workplace burnout was observed.

Winer began by defining workplace burnout, emphasizing that it is not exclusive to oncology, and that many oncologists resist burnout by focusing on the mission-driven nature of the work. Then, he speculated how oncologist burnout may have increased from 2013 to 2023, suggesting that it may have been related to a larger societal trend due to increased awareness of it. Furthermore, he suggested that the COVID-19 pandemic may have exacerbated fatigue, as well as the growing utilization of telehealth and documentation, which take oncologists away from personal engagement with patients.

He then explored how the workforce might be impacted by burnout, highlighting a sizable percentage of oncologists who claim to be nearing retirement age. Based on this trend, there may be a need for workforce expansion, as well as the need to embrace a more multidisciplinary approach to help oncologists deliver patient care. Winer concluded by outlining how he mitigates burnout personally, as well as his thoughts regarding how oncology has progressed since his career began.

Schenkel C, Levit LA, Kirkwood K, et al. State of professional well-being, satisfaction, and career plans among US oncologists in 2023. 

 Published online January 29, 2025. doi:10.1200/OA.24.00010

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

2025 American Society of Clinical Oncology (ASCO) Annual Meeting,

 spoke with a variety of oncology experts about the late-breaking abstracts, plenary sessions, and other key presentations that may shift the paradigm across different cancer care fields. They highlighted anticipated clinical trial results that may transform the standard of care for gynecologic malignancies, lung cancer, and other disease types.

Rachel N. Grisham, MD, section head of Ovarian Cancer and director of gynecologic medical oncology at Memorial Sloan Kettering Westchester in New York, shared her anticipation of findings from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. She stated she was excited to see whether the data may represent a new opportunity for this patient population.

Next, MinhTri Nguyen, MD, a medical oncologist and hematologist at Stanford Health Care in San Jose, California, highlighted a few breast cancer presentations to look out for. These topics included a plenary session on data from the phase 3 SERENA-6 study (NCT04964934) evaluating camizestrant in combination with CDK4/6 inhibitors for patients with hormone receptor–positive, HER2-negative advanced breast cancer harboring emergent 

Additionally, Eric K. Singhi, MD, an assistant professor in the Department of General Oncology in the Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, spoke about a range of potentially practice-changing results in the lung cancer field. For example, he described a session focused on primary results of the phase 3 IMforte trial (NCT05091567) assessing lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) for patients with extensive-stage small cell lung cancer. According to Singhi, data from IMforte may shift the paradigm of maintenance therapy for this population.

In the world of head and neck cancer, Douglas R. Adkins, MD, associate professor of Internal Medicine, Division of Oncology, Section of Medical Oncology at Washington University Medicine in St Louis, Missouri, highlighted the session on the phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417). Investigators evaluated nivolumab (Opdivo) in combination with chemoradiotherapy for those with resected head and neck squamous cell carcinoma. Adkins is eager to see how these data may impact the standard of care, particularly for patients in Europe, where investigators conducted the study.

discussion, Benjamin Garmezy, MD,  associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and a medical oncologist at SCRI Oncology Partners in Nashville, Tennessee, discussed key abstracts in bladder cancer. One specific presentation included additional findings from the phase 3 NIAGARA trial (NCT03732677), which may show how circulating tumor DNA can influence treatment decision-making regarding perioperative durvalumab (Imfinzi) for patients with muscle-invasive bladder cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

, Viviana Cortiana, MS4, and Yan Leyfman, MD, spoke about their manuscript titled “Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity,” which they published in the 

Cortiana is a medical student in the Department of Medical and Surgical Sciences at the University of Bologna. Leyfman is a resident physician from the Icahn School of Medicine of the Mount Sinai Health System.

Cortiana highlighted how artificial intelligence (AI)–based tools may mitigate the overdiagnosis of cancers, although she noted a need to validate these devices with diverse and high-quality data sets to avoid the risk of biased models. Additionally, she described how developing population-specific AI models may improve predictive accuracy in diagnosis as well as treatment planning, which can especially benefit patients in low- and middle-income countries.

As part of ethically applying the use of AI to oncology and delivering equitable cancer care, Leyfman emphasized core pillars such as data security, transparency, clinical validation, and combatting algorithmic bias. Furthermore, he stated that potential applications of these tools include mobile diagnostics, cloud-based platforms, and remote consultation, which can help increase access to care. Regarding the potential next steps in the field, he highlighted that global partnerships with parties such as technology companies, governments, and nongovernmental organizations may assist with the funding and deployment of AI tools, especially for underserved regions.

“The future of AI in oncology is increasingly promising, not just in pushing the boundaries of what's possible in cancer care but also making sure that more precise and more accessible worldwide therapies are available,” Leyfman stated. “AI has the potential to fundamentally change how we detect, treat, and monitor [cancer], but realizing that promise, especially in a way that's equitable, will require collaboration, validation, thoughtful implementation, and a commitment to leaving no patient behind.”

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discussed the highly anticipated 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bupathi is the executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers, and Garmezy is the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at SCRI and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, underscored the curative potential of adjuvant therapy in kidney cancer.

During the discussion, the experts highlight the abstracts that have caught their eye and offer their predictions on the data that could reshape the landscape of genitourinary oncology.

Several intriguing abstracts are highlighted, with a focus on the evolving role of immunotherapy and the potential for novel combinations.

Phase 3 PDIGREE trial (NCT03793166): Immunotherapy plus nivolumab (Opdivo) and ipilimumab (Yervoy) followed by nivolumab alone or nivolumab with cabozantinib (Cabometyx) for patients with advanced kidney cancer. This will be presented by Tian Zhang, MD, MHS, on May 31 from 1:27-1:33 pm CDT.

Phase 1b STELLAR-002 trial (NCT05176483): Zanzalintinib plus nivolumab and relatlimab in patients with advanced solid tumors. This will be presented by Benjamin Garmezy, MD, in a poster presentation on June 2 at 2:30 pm CDT.

The Bupathi and Garmezy suggest we should be on the lookout for data that could refine treatment algorithms and identify new biomarkers to guide therapy selection.

The potential impact of neoadjuvant therapy and the role of circulating tumor DNA (ctDNA) analysis were key discussion points. The experts anticipated seeing updates from ongoing trials exploring the utility of ctDNA as a predictive and prognostic biomarker, potentially allowing for more personalized treatment approaches.

Phase 3 NIAGARA trial (NCT03732677): ctDNA will be assessed in those who received perioperative durvalumab (Imfinzi) for muscle-invasive bladder cancer. This will be presented by Thomas Pwles, MD, PhD, FCRP, on June 1 from 10:45-10:57 am CDT.

Phase 3 Checkmate901 (NCT03036098): Nivolumab plus ipilimumab vs gemcitabine/carboplatin in patients who are previously untreated with unresectable or metastatic urothelial carcinoma. This will be presented by Michael Simon Van Der Heijden, MD, PhD, on June 1 from 9:45-9:57 am CDT.

A significant portion of the discussion revolves around prostate cancer, with several potentially practice-changing abstracts generating excitement.

Artificial intelligence (AI): The use of a multimodal AI model to determine the benefit from a second-generation androgen receptor pathway inhibitor for patients who are high-risk and have non-metastatic prostate cancer and were enrolled on the phase 2/3 STAMPEDE trial (NCT00268476). This will be presented by Nicholas David James, PhD, FRCP, MBBS, on June 3 from 9:57-10:09 am CDT.

Radiation therapy: A phase 3 trial assessing CAN-2409 plus prodrug and standard of care external beam radiation therapy in patients with newly diagnosed localized prostate cancer. This will be presented by Theodore L. De-Weese, MD, on June 3 from 9:45-9:57 am CDT.

Furthermore, the conversation touched upon anticipated phase 3 data in hormone-sensitive prostate cancer. Specifically, there’s excitement around upcoming results for patients with high-risk or high-volume metastatic hormone-sensitive prostate cancer harboring 

 mutations. This data could be practice-changing and offer a new therapeutic avenue for this specific subset of patients.

Beyond these specific disease areas, the podcast highlighted the broader themes expected at 2025 ASCO, including the continued development and refinement of immunotherapy, the integration of multimodal AI in oncology, and the ongoing investigation of novel targets, like TROP2 inhibitors.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO. 

A Sneak Peek at 2025 ASCO From the GU Perspective

In a conversation with CancerNetwork®, Viviana Cortiana, fourth-year medical student in the Department of Medical and Surgical Sciences at the University of Bologna, and Yan Leyfman, MD, a resident physician from the Icahn School of Medicine of the Mount Sinai Health System, discussed their publication in the 

 titled “Expanding Horizons in T-cell Lymphoma Therapy: A Focus on Personalized Treatment Strategies.” Throughout the discussion, the authors spoke about the current lymphoma landscape, chimeric antigen receptor (CAR) T-cell therapy, and the evolving understanding of the tumor microenvironment.

Specifically, Cortiana covered a shift from histology-based classification to molecular tumor type classification using next-generation sequencing as well as a growing interest in biomarker-driven therapies. Regarding the limited efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in T-cell lymphoma, she listed potential advances in combination therapies for angioimmunoblastic T-cell lymphoma, which include combining PI3K and HDAC inhibition as well as CD30- and TRBC1-targeting CAR T-cell therapies.

Furthermore, Leyfman discussed strategies that “reprogram” the microenvironment to address malignant T cells, particularly through epigenetic and adoptive cell therapies. Leyfman concluded by discussing future implications for T-cell lymphoma treatment, emphasizing an emergence of precision medicines and armored CAR engineering strategies.

 outlined the available treatment options for peripheral T-cell lymphoma (PTCL), which include targeted therapies through EZH2 inhibition, chemotherapy with CHOP, CAR T-cell therapies, and allogeneic stem cell transplantation. Additionally, they highlighted encouraging results from clinical trials evaluating epigenetic-targeted therapies through the identification of molecular aberrations, which can help tailor treatments to individual patients.

Furthermore, the article explored limitations of chemotherapy as well as autologous stem cell transplantation (ASCT), which may not be feasible for older patients or those with comorbidities. Authors suggested that targeted therapies may enhance tumor specificity while reducing systemic toxicity. Given the risks associated with ASCT, they emphasized a focus on the incorporation of optimized treatment strategies, such as novel pharmaceuticals and combination therapies, into clinical practice for patients with PTCL.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

 and the American Society for Transplantation and Cellular Therapy (ASTCT) program 

Nora M. Gibson, MD, MSCE, and Taha Al-Juhaishi, MD, spoke about real-world applications of betibeglogene autotemcel (beti-cel; Zynteglo) as a treatment for patients with β-thalassemia. They spoke in the context of a study that Gibson presented at the 

 which evaluated patients who received commercial beti-cel in a single-center cohort following 

Gibson is a fourth-year fellow in bone marrow transplant and cellular therapy at the Children's Hospital of Philadelphia (CHOP), with a background in clinical research and epidemiology. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine.

Findings from Gibson’s study revealed that among 10 patients who underwent stem cell collection at CHOP from 2022 to 2024, beti-cel yielded consistent red blood cell transfusion independence, with investigators noting prolonged platelet engraftment time and high platelet transfusion requirements. Beyond these findings, the conversation focused on how beti-cel compares with other currently available gene therapies for patients with hemoglobin disorders as well as noncurative therapies such as allogeneic stem cell transplantation. Gibson and Al-Juhaishi also discussed strategies for mitigating occlusive disease and other potential toxicities associated with beti-cel.

“It's a really exciting time to be working in this field, where we finally have really good options for these patients. From our experience and from clinical trials, beti-cel and likely exagamglogene autotemcel [Casgevy]...are very effective, curative therapies for thalassemia in the real-world setting, and we've seen very similar results in sickle cell disease,” Gibson said. “These therapies have been life-changing for our patients, and they've had a huge reduction in their symptoms and a huge reduction in their burden of health care that's required.”

Gibson NM, Friedman DF, Elgarten CW, et al. Post-approval, real-world experience with betibeglogene autotemcel for transfusion-dependent beta thalassemia. 

 2025;31(2):S254. doi:10.1016/j.jtct.2025.01.386

FDA approves first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions. News release. FDA. August 17, 2022. Accessed April 21, 2025. https://tinyurl.com/3vrkk8kz

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, dove into the complexities of adjuvant therapy for kidney cancer, providing valuable insights for oncology clinicians in the latest episode of 

. The discussion began with a fundamental overview of adjuvant therapy, which aims to eradicate residual microscopic disease and mitigate the risk of cancer recurrence.

Bupathi, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers, and Garmezy, associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at SCRIand medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, underscored the curative potential of adjuvant therapy in kidney cancer.

The discussion also focused on 2 primary modalities of adjuvant therapy: targeted therapies and immunotherapy. Targeted therapies, particularly VEGF tyrosine kinase inhibitors, were discussed in the context of clear cell kidney cancer, the predominant subtype, where they inhibit the VEGF signaling pathway to impede cancer cell growth.

Bupathi and Garmezy spoke about results from the phase 3 KEYNOTE-564 trial (NCT03142334), which led to the FDA approval of pembrolizumab (Keytruda) for high-risk clear cell kidney cancer.

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Podcasts

All Podcast Series

Recent Episodes

Oncology On the Go With ASTCT Talks

ONCOLOGY Decoded

FDA Approval Alert: The Need-to-Know